Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexmedetomidine on Propofol Requirement During Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. ASA physical status I/II~2. Undergoing elective laparoscopic / robotic surgery of more than 60-minutes duration~Exclusion Criteria:~1. Cardiovascular disorders (uncontrolled hypertension, Atrio-ventricular block, sinus bradycardia, congenital heart disease, reduced LV compliance \& diastolic dysfunction)~2. Neurological disorders (previous neurosurgery, psychiatric disorders, autonomic nervous system disorders- orthostatic hypotension, transient ischemic attacks)~3. Any hepato-renal insufficiency~4. Uncontrolled diabetes mellitus~5. Known allergy/hypersensitivity to study drug~6. Pulmonary dysfunction (restrictive /obstructive lung disease)~7. Acute/chronic drug dependence/substance abuse

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine group (Type: ACTIVE_COMPARATOR): Patients will receive a pre-induction loading dose of dexmedetomidine 1-µ/kg over 10 minutes followed by an intraoperative infusion of 0.5-µ/kg/hour . Over and above the use of study drug dexmedetomidine propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients
- Non-Dexmedetomidine group (Type: PLACEBO_COMPARATOR): Patients will receive a pre-induction loading dose of 0.9% saline solution over 10 minutes followed by an intraoperative infusion.Over and above the use of 0.9% saline solution propofol administration will be controlled with Closed Loop Anaesthesia Delivery system to maintain a consistent anaesthetic depth (BIS 40-60) using bispectral index monitor in all the patients

Based on this trial design, predict the completion outcome and termination type (if applicable).